Marker | Genotype | Patient | Control | OR (95Â % CI) | P value |
---|---|---|---|---|---|
UCP2 I/D | |||||
 | DD | 149 (57.6 %) | 94 (47.0 %) | Reference |  |
 | ID | 70 (27.6 %) | 82 (41.0 %) | 0.5 (0.3–0.8) | 0.003* |
 | II | 38 (14.8 %) | 24 (12.0 %) | 1.3 (0.7–2.2) | 0.4 |
 | D | 368 (71.6 %) | 270 (67.5 %) | Reference |  |
 | I | 146 (28.4 %) | 130 (32.5 %) | 1.2 (0.9–1.6) | 0.2 |
Dominant model | |||||
 | DD versus II + ID |  |  | 1.2 (0.8–1.7) | 0.2 |
Recessive model | |||||
 | II versus ID + DD |  |  | 0.7 (0.45–1.3) | 0.4 |
Leptin-2548 G/A | |||||
 | GG | 90 (35.0 %) | 82 (41.0 %) | Reference |  |
 | GA | 99 (38.5 %) | 92 (46.0 %) | 1.2 (0.8–1.9) | 0.39 |
 | AA | 68 (26.5 %) | 26 (13.0 %) | 2.0 (1.2–3.3) | 0.007* |
 | G | 279 (54.3 %) | 256 (64.0 %) | Reference |  |
 | A | 235 (45.7 %) | 144 (36.0 %) | 1.5 (1.1–1.9) | 0.003* |
Dominant model | |||||
 | GG versus GA + AA |  |  | 0.27 (0.1–0.4) | 0.001* |
Recessive model | |||||
 | AA vs. GG + GA |  |  | 1.8 (1.1–2.9) | 0.012* |
Ghrelin Arg51Gln | |||||
 | GG | 164 (63.8 %) | 142 (71.0 %) | Reference |  |
 | GA | 75 (29.2 %) | 53 (26.5 %) | 1.2 (0.8–1.8) | 0.33 |
 | AA | 18 (7.0 %) | 5 (2.5 %) | 3.4 (1.2–7.5) | 0.02* |
 | G | 403 (78.4 %) | 337 (84.3 %) | Reference |  |
 | A | 111 (21.6 %) | 63 (15.7 %) | 1.6 (1.1–2.1) | 0.02* |
Dominant model | |||||
 | GG versus GA + AA |  |  | 0.7 (0.4–1.0) | 0.1 |
Recessive model | |||||
 | AA versus GG + GA |  |  | 2.9 (1.0–8.0) | 0.003* |
Ghrelin Leu72Met | |||||
 | CC | 178 (69.3 %) | 141 (70.5 %) | Reference |  |
 | CA | 51 (19.8 %) | 50 (25.0 %) | 0.8 (0.5–1.3) | 0.2 |
 | AA | 28 (10.9 %) | 9 (4.5 %) | 2.5 (1.2–5.4) | 0.02* |
 | C | 407 (79.2 %) | 332 (83.0 %) | Reference |  |
 | A | 107 (20.8 %) | 68 (17.0 %) | 1.3 (0.9–1.8) | 0.15 |
Dominant model | |||||
 | CC versus CA + AA |  |  | 1.07 (0.7–1.6) | 0.75 |
Recessive model | |||||
 | AA versus CC + CA |  |  | 2.58 (1.2–5.6) | 0.01* |